Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...

The factor that tips you over the edge from being at risk for a disease to actually developing the disease is not always ...

Researchers from Osaka University find that peristaltic pump action and high shear flow forces promote amyloid nucleation.

Researchers from Osaka University found that peristaltic pump flow mechanically breaks supersaturation to induce amyloid ...

Brain inflammation, while a crucial part of the body's immune response, takes on a detrimental role in Alzheimer's disease.

More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...

Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s disease. The technology ...